Retatrutide Raw Ingredient | Laboratory Use | For Research Only

Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively. In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

Horwats Biotech ,Jiangsu Horwats Biopharmaceutical Co., Ltd., headquartered in Suqian, Jiangsu Province, China, is a comprehensive high-tech enterprise integrating R&D and sales. With strong foundations in synthetic biology, protein purification technology, and fermentation engineering, we are committed to producing high-purity natural active ingredients and pharma-grade raw materials 503A and 503B Compounding Pharmacy.

Backed by the scientific resources of Jiangnan University and supported by strategic partnerships with Nanjing Horwats Biotech Co., Ltd. and Nantong Juke Biotech Co., Ltd., Horwats Biotech continues to innovate and expand its influence across the pharmaceutical, nutraceutical, and wellness industries.